EGenesis is a Biotech company based in Cambridge. It has raised $481M in total funding. Latest round: Series D.
EGenesis funding overview
EGenesis is a Biotech company based in Cambridge. EGenesis has raised $481M in total disclosed funding. That places its disclosed total in the $250M–$1B range. Its most recent disclosed round is a Series D announced in September 2024. The round record for EGenesis runs through 2024; nothing later has been disclosed. Investors on record include Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures and 6 others. 12 distinct backers are named across the disclosed rounds.
EGenesis at a glance
Total raised
$481M
Latest round
Series D
Latest round date
September 2024
Industry
Biotech
Headquarters
Cambridge
Notable investors
Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures, Leaps by Bayer, DaVita
Frequently asked about EGenesis funding
How much has EGenesis raised?
EGenesis has raised $481M in total disclosed funding across the rounds on record.
Who has invested in EGenesis?
Lux Capital, ARCH Ventures, Khosla Ventures, Farallon Capital Management, Alta Partners, Fresenius Medical Care Ventures are named among the investors backing EGenesis.
What was the latest EGenesis funding round?
The most recent disclosed round is a Series D, announced in September 2024.
Where is EGenesis based?
EGenesis is based in Cambridge.
What sector does EGenesis operate in?
EGenesis is tracked under Biotech from Cambridge, with $481M in disclosed funding.
When did EGenesis last raise?
The last disclosed EGenesis round closed in September 2024 at Series D.
We update the EGenesis record whenever a new round is filed or announced, so the totals above track the public record rather than estimates. Related Biotech companies in Cambridge and their backers are listed below.
